


CTCatch™ Test Process



New Era of Precision Medicine


Abnova Diagnostics Japan
CTCatch™ Test



Address: National Cancer Center Research Institute
3F5 Chome-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 Japan
Tel: + 81 3 6264 3448 Fax: + 81 3 6264 3449
www.abnovadx.com

Precision Medicine Leads the Next Medical Revolution


Precision medicine takes into account individual's variability in genes, environment and lifestyle, and approaches each person with personalized diagnosis and treatment.



With its unique advantage in precision medicine, Abnova Diagnostics Japan has integrated circulating tumor cell (CTC) enrichment, cell-surface vimentin antibody, and mutaFISH™ technologies and developed CTCatch™ for CTC detection. This service can bring new insights into cancer diagnosis, monitoring and treatments.


Companion Diagnostics Help Patients Select Appropriate Treatments

Companion diagnostics can identify patients who would benefit from particular therapeutics and provide information on drug safety and effectiveness. For example, HER2 gene detection helps determine if Herceptin is an appropriate treatment for breast cancer patients.



Liquid Biopsy vs Traditional Biopsy

Liquid biopsy is not limited to tumor locations. CTC liquid biopsy can detect protein expression and gene mutation in tumor cells from blood.



Blood-Based Tumor Diagnosis

Analyzing CTCs, circulating tumor DNA (ctDNA) and exosomes, and their gene mutations can improve personalized diagnosis, disease monitoring, and treatments.

